At a threshold of US$6,700 per quality-adjusted life year, adjuvant osimertinib, adjuvant alectinib and neoadjuvant nivolumab were cost-effective in Sri Lanka; at US$3,000 only the osimertinib strategies remained so.
A Markov cost-utility model from the Sri Lankan health system's perspective compared adjuvant, neoadjuvant, perioperative and consolidation targeted and immunotherapies for stage II to III NSCLC, with sex-specific analyses, a lifetime horizon and a 5-year budget impact for the therapies found cost-effective.
A worked example of how the free state system could rank costly lung cancer drugs and what price cuts would bring others within reach.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/